Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 33

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 33
---
 ● | continue to recruit and retain adequate numbers of effective and experienced sales and marketing personnel; |

| ● | effectively train our sales and marketing personnel in the benefits and risks of our products; |

| ● | establish and maintain successful sales, marketing, training and education programs that educate health 
 care professionals so they can appropriately inform their patients about our products;                  |

| ● | manage geographically dispersed sales and marketing operations; and |

| ● | effectively train our sales and marketing personnel on the applicable fraud and abuse laws that govern                                     
 interactions with healthcare practitioners as well as current and prospective patients and maintain active oversight and auditing measures 
 to ensure continued compliance.                                                                                                            |

We may not be able to successfully
manage our sales force or increase our product sales at acceptable rates.

We have limited experience in marketing and selling our products and related services, and if we are unable to successfully commercialize our products and related services, our business and operating results will be adversely affected.

We only recently received CE
Mark approval in the EU for our first product, the Lumee Oxygen Platform, and accordingly we have limited experience marketing and selling
our products and related services. Sales of our Lumee Oxygen Platform in the EU will depend on our ability to maintain CE Mark approval,
including requirements to comply with European Medical Devices Regulation and renew the CE Mark as required. Sales of Lumee Oxygen Platform
outside of the EU, including in the U.S., and sales of Lumee Glucose in any jurisdiction, will depend on our ability to obtain and maintain
applicable regulatory approvals in such jurisdictions. Following regulatory approvals, future sales of our products will depend in large
part on our ability to effectively market and sell our products and services, successfully manage and expand our sales force, and increase
the scope of our marketing efforts. We may also enter into distribution arrangements in the future. Because we have limited experience
in marketing and selling our products, our ability to forecast demand, the infrastructure required to support such demand and the sales
cycle to customers is unproven. If we do not build an efficient and effective marketing and sales force, our business and operating results
will be adversely affected.

We are subject to a variety of risks due to our international operations that could adversely affect our business, our operations or profitability and operating results.

We are not currently generating
revenues in international countries. We currently operate clinical trial studies internationally in Vietnam, Germany and Austria and intend
to continue to pursue growth opportunities outside the United States and we may increase our use of administrative